Defining the role of antiandrogens in the treatment of prostate cancer

Urology

Volumn 47, Issue 1 SUPPL. 1, 1996, Pages 85-89

  McLeod, David G ^a   Kolvenbag, Geert J C M ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN DERIVATIVE; LEUPRORELIN; MEGESTROL ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER COMBINATION CHEMOTHERAPY; CASTRATION; CLINICAL PROTOCOL; CONFERENCE PAPER; DOSE RESPONSE; DRUG HALF LIFE; DRUG SAFETY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; MASTALGIA; METASTASIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RECURRENT CANCER; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOGENICITY;

ANDROGEN ANTAGONISTS; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 0029591491     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(96)80014-8     Document Type: Article

References (23)

1. Dorfman RI: Biological activity of antiandrogens. Br J Urol 82 (suppl): 3-8, 1970.
2. Neumann F, and Jacobi CH: Antiandrogens in tumor therapy. Clin Oncol 1: 41-66, 1982.
3. Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, and Sylvester R Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136: 624-630, 1986.
4. Venner PM, Klotz PG, Klotz LH, Stewart DJ, Davis IR, Orovan WL, and Ramsey EW: Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate. Semin Oncol 15 (suppl): 62-67, 1988.
5. Delaere KP, and Van Thillo EL: Flutamide monotherapy as a primary treatment in advanced prostatic carcinoma. Semin Oncol 18 (suppl 6): 13-18, 1991.
6. MacFarlane JR, and Tolley DA: Flutamide therapy for advanced prostatic cancer: a phase II study. Br J Urol 57: 172-174, 1985.
7. Sogani PC, Vagaiwala MR, and Whitemore WF Jr: Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54: 744-750, 1984.
8. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
9. Wysowski DK, Freiman JP, Tourtelot JB, and Horton ML 3d: Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118: 860-864, 1993.
10. McConnell ND, and Livingston RB: Severe reversible neutropenia following treatment of prostate cancer with flutamide. J Ural 151: 1353-1354, 1994.
11. 2 prostate cancer, in Murphy GP, Kuss R, Khoury S, and Chatelain C (Eds): Prostate Cancer Part A: Research, Endocrine Treatment and Histopathology, vol. 243A. New York, Alan R. Liss, 1987, pp 391-400.
12. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, et al.: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149: 77-83, 1993.
13. Decensi AU, Boccardo F, Guameri D, Positano N, Paoletti MC, Costantini M, Martorana G, and Giuliani L: Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 146: 377-381, 1991.
14. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, and Kolvenbag G: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology 45: 745-752, 1995.
15. National Inpatient Profile October 1992-September 1993, HCIA, Inc. 1994.
16. Lepor H, Kimball AW, and Walsh PC: Cause specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol 141: 82-84, 1989.
17. Catalona WJ, Miller DR, and Kavoussi LR: Intermediate-term survival results in clinically understaged prostate patients following radical prostatectomy. J Urol 140: 540-543, 1988.
18. Zincke H, Utz DC, and Taylor WF: Bilateral pelvic lymph-adenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 135: 1199-1205, 1986.
19. Stein A, deKernion JB, Smith RB, Dorey F, and Patel H: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 147: 942-946, 1992.
20. Frazier HA, Robertson JE, Humphrey PA, and Paulson DF: Is prostate specific antigen of clinical importance in evaluating out-come after radical prostatectomy? J Urol 149: 516-518, 1993.
21. Cheng WS, Frydenburg M, Bergstrahl EJ, Larson-Keller JJ, and Zincke H: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 42: 283-291, 1993.
22. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 1992.
23. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, and Porter A: Phase III trial of androgen suppression using goserelin in unfavorable prognosis of carcinoma of the prostate treated with definitive radiotherapy (report of RTOG Protocol 85-31). Proc Am Soc Clin Oncol 14: 239, 1995.